The clinical study will be conducted within the framework of the Diabetic Foot Unit, a globally recognized institution with deep expertise in diabetes-related complications, including peripheral neuropathy and diabetic foot ulcers.

– This collaboration marks an important step in our efforts to establish the VibroSense Meter II as a clinically valuable tool. We are honored to work with such a highly respected research environment as the Complutense University of Madrid, says Tarik Cengiz, CEO of VibroSense Dynamics.

The aim of the study is to investigate whether the VibroSense Meter II can offer clinical benefits compared to today’s established methods for detecting diabetes-related nerve damage. By objectively comparing the results, the parties hope to evaluate whether the technology can contribute to earlier and more accurate diagnosis of peripheral neuropathy in diabetic patients.

– We look forward to evaluating the VibroSense Meter II as a potential complement to current clinical methods. Early detection of peripheral neuropathy is crucial for preventing serious complications, and we welcome new technologies that may support improved diagnostics and patient care, says Professor José Luis Lázaro Martínez, Head of the Diabetic Foot Unit at the Complutense University of Madrid.

The VibroSense Meter II is a diagnostic system that measures vibration perception at multiple frequencies and is designed to detect early signs of nerve impairment. The technology has the potential to support clinical decision-making and enhance the quality of care for patients with diabetes.

For further information, please contact:
Tarik Cengiz, CEO
VibroSense Dynamics AB
Phone: +46 (0)40 88 026
Email: info@vibrosense.com
Website: www.vibrosense.com

 “The new Gold Standard for reliable detection of nerve damage”

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical devices and services to support the diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to sense vibrations at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers.

Our vision is for the company's products to become a standard tool in all neurological examinations, helping to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.